AMAG Pharma (AMAG) Misses Q3 EPS by 16c; Boosts FY15 Outlook

AMAG Pharma (NASDAQ: AMAG) reported Q3 EPS of $1.02, $0.16 worse than the analyst estimate of $1.18. Revenue for the quarter came in at $103.5 million versus the consensus estimate of $113.88 million.

AMAG Pharma sees FY2015 revenue of $425-450 million, versus prior guidance of $395-430 million and the consensus of $444.4 million.

For earnings history and earnings-related data on AMAG Pharma (AMAG) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
• Newton Golf Company (NWTG) Reports Q2 Loss of $0.49